These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 18794727

  • 1. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
    Geese WJ, Achanzar W, Rubin C, Hariharan N, Cheng P, Tomlinson L, Ordway N, Dracopoli NC, Delmonte T, Hui L, Krishnan B, Cosma G, Ranade K.
    Pharmacogenet Genomics; 2008 Oct; 18(10):903-10. PubMed ID: 18794727
    [Abstract] [Full Text] [Related]

  • 2. Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist farglitazar.
    Spraggs C, McCarthy A, McCarthy L, Hong G, Hughes A, Lin X, Sathe G, Smart D, Traini C, Van Horn S, Warren L, Mosteller M.
    Pharmacogenet Genomics; 2007 Dec; 17(12):1065-76. PubMed ID: 18004211
    [Abstract] [Full Text] [Related]

  • 3. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
    Rogue A, Renaud MP, Claude N, Guillouzo A, Spire C.
    Toxicol Appl Pharmacol; 2011 Jul 01; 254(1):18-31. PubMed ID: 21515302
    [Abstract] [Full Text] [Related]

  • 4. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
    Tan Y, Muise ES, Dai H, Raubertas R, Wong KK, Thompson GM, Wood HB, Meinke PT, Lum PY, Thompson JR, Berger JP.
    Mol Pharmacol; 2012 Jul 01; 82(1):68-79. PubMed ID: 22496518
    [Abstract] [Full Text] [Related]

  • 5. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
    Waites CR, Dominick MA, Sanderson TP, Schilling BE.
    Toxicol Sci; 2007 Nov 01; 100(1):248-58. PubMed ID: 17675651
    [Abstract] [Full Text] [Related]

  • 6. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C, Fruchart JC, Staels B.
    Curr Opin Pharmacol; 2006 Dec 01; 6(6):606-14. PubMed ID: 16973418
    [Abstract] [Full Text] [Related]

  • 7. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB.
    Curr Opin Nephrol Hypertens; 2008 May 01; 17(3):282-5. PubMed ID: 18408479
    [Abstract] [Full Text] [Related]

  • 8. Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
    Achanzar WE, Moyer CF, Marthaler LT, Gullo R, Chen SJ, French MH, Watson LM, Rhodes JW, Kozlosky JC, White MR, Foster WR, Burgun JJ, Car BD, Cosma GN, Dominick MA.
    Toxicol Appl Pharmacol; 2007 Sep 15; 223(3):246-56. PubMed ID: 17663016
    [Abstract] [Full Text] [Related]

  • 9. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S, Matter H, Schönafinger K, Glien M, Mathieu M, Marquette JP, Michot N, Haag-Diergarten S, Urmann M, Wendler W.
    ChemMedChem; 2011 Apr 04; 6(4):633-53. PubMed ID: 21400663
    [Abstract] [Full Text] [Related]

  • 10. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.
    Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, Kopelovich L, Glazer RI.
    Cancer Res; 2005 May 01; 65(9):3950-7. PubMed ID: 15867396
    [Abstract] [Full Text] [Related]

  • 11. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.
    Hansen L, Ekstrøm CT, Tabanera Y Palacios R, Anant M, Wassermann K, Reinhardt RR.
    J Clin Endocrinol Metab; 2006 Sep 01; 91(9):3446-50. PubMed ID: 16822823
    [Abstract] [Full Text] [Related]

  • 12. Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo.
    Kumar AP, Quake AL, Chang MK, Zhou T, Lim KS, Singh R, Hewitt RE, Salto-Tellez M, Pervaiz S, Clément MV.
    Cancer Res; 2009 Nov 15; 69(22):8636-44. PubMed ID: 19887620
    [Abstract] [Full Text] [Related]

  • 13. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
    Lecka-Czernik B.
    IDrugs; 2010 Nov 15; 13(11):793-801. PubMed ID: 21046527
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Suppression of retinal peroxisome proliferator-activated receptor gamma in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase.
    Tawfik A, Sanders T, Kahook K, Akeel S, Elmarakby A, Al-Shabrawey M.
    Invest Ophthalmol Vis Sci; 2009 Feb 15; 50(2):878-84. PubMed ID: 18806296
    [Abstract] [Full Text] [Related]

  • 16. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis.
    Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, Leask A.
    Arthritis Rheum; 2009 Sep 15; 60(9):2822-9. PubMed ID: 19714649
    [Abstract] [Full Text] [Related]

  • 17. Anti-inflammatory properties of a dual PPARgamma/alpha agonist muraglitazar in in vitro and in vivo models.
    Paukkeri EL, Leppänen T, Lindholm M, Yam MF, Asmawi MZ, Kolmonen A, Aulaskari PH, Moilanen E.
    Arthritis Res Ther; 2013 Apr 17; 15(2):R51. PubMed ID: 23594962
    [Abstract] [Full Text] [Related]

  • 18. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.
    Arch Pharm Res; 2009 May 17; 32(5):721-7. PubMed ID: 19471887
    [Abstract] [Full Text] [Related]

  • 19. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states.
    Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, Mu J, Thompson JR, Berger JP, Wong KK.
    Mol Pharmacol; 2008 Aug 17; 74(2):403-12. PubMed ID: 18467542
    [Abstract] [Full Text] [Related]

  • 20. Novel oxazole containing phenylpropane derivatives as peroxisome proliferator activated receptor agonists with hypolipidemic activity.
    Pingali H, Raval S, Raval P, Makadia P, Zaware P, Goel A, Suthar D, Jain M, Patel P.
    Pharmazie; 2008 Jul 17; 63(7):497-502. PubMed ID: 18717481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.